Peer-Reviewed Publications

CPCE investigators are international experts in their clinical effectiveness-related fields, and have authored hundreds of pediatric research articles in leading peer-reviewed journals. From here you can access CPCE journal article abstracts by author, title, or year.

Found 136 results
Author Title [ Year(Asc)]
Search results for Aplenc  [Reset Search]
Chisholm KM, Heerema-McKenney AE, Choi JK, et al. "Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group." Blood Adv. 2020;4(23):6000-6008.
Aplenc R, Meshinchi S, Sung L, et al. "Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group." Haematologica. 2020.
Ding Y-Y, Ramakrishna S, Long AH, et al. "Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic." Pediatr Blood Cancer. 2020:e28427.
Diorio C, Shaw PA, Pequignot E, et al. "Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children." Blood Adv. 2020;4(20):5174-5183.
Getz KD, Sung L, Alonzo TA, et al. "Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group." J. Clin. Oncol.. 2020:JCO1902856.
Hoff FW, van Dijk AD, Qiu YHua, et al. "Heat Shock Factor 1 (HSF1-pSer326) Predicts Response to Bortezomib-Containing Chemotherapy in Pediatric AML: A COG Study." Blood. 2020.
Cahen VC, Li Y, Getz KD, et al. "Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment." Pediatr Blood Cancer. 2020:e28315.
Arnold SD, Brazauskas R, He N, et al. "The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization." Biol. Blood Marrow Transplant.. 2020.
Brodersen LEidenschin, Gerbing RB, M Pardo L, et al. "Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report." Blood Adv. 2020;4(20):5050-5061.
Cooper TM, Absalon MJ, Alonzo TA, et al. "Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group." J. Clin. Oncol.. 2020:JCO1903306.
Bona K, Li Y, Winestone LE, et al. "Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma." J Natl Cancer Inst. 2020.
Wang ES, Aplenc R, Chirnomas D, et al. "Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia." Leuk. Lymphoma. 2020:1-9.
Aplenc R. "Venetoclax for paediatric acute myeloid leukaemia: a step forward." Lancet Oncol.. 2020;21(4):476-478.